After Biogen's (BIIB) '537 EU patent was revoked, JMP Securities thinks the news is positive for Forward Pharma (FWP). According to the firm, Forward now has the only patent in Europe for a 480 mg Dimethyl fumarate drug for the treatment of MS. The firm keeps a $33 price target and Outperform rating on Forward.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here